• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23874 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2023     National Authority for Assessment and Accreditation in Healthcare (INEAS) [Autologous adipose-derived stem cells for chronic wounds treatment : Full HTA report]
2010     Committee for New Health Technology Assessment (CNHTA) [Autofluorescence image(endoscopy)]
2009     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Autism treatment with orthomolecular therapy]
2018     Haute Autorite de sante (HAS) [Autism spectrum disorder: Warning signs, detection, diagnosis and assessment in children and adolescents]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Autism spectrum disorder: scientific knowledge about the detection, diagnosis and treatment]
2022     Basque Office for Health Technology Assessment (OSTEBA) [Autism spectrum disorder: scientific evidence on its detection, diagnosis and treatment]
2009     The Regional Health Technology Assessment Centre (HTA-centrum) [Auricular acupuncture for narcotic dependency]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Auditory integration therapy for autism spectrum disorders]
2009     Committee for New Health Technology Assessment (CNHTA) [Auditory cortex stimulation]
2000     Basque Office for Health Technology Assessment (OSTEBA) [Auditive implants: concept, indications and appropriate use]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [AUDIT ONCOrisk: Quality of the information in the study about digestive oncological surgery results]
2008     Committee for New Health Technology Assessment (CNHTA) [ATP7A gene, mutation[sequencing]]
2008     Committee for New Health Technology Assessment (CNHTA) [ATP7A gene, mutation analysis]
2017     Basque Office for Health Technology Assessment (OSTEBA) [ATOMs – Adjustable Transobturator Male System. Device for urinary incontinence]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atidarsagene autotemcel/OTL-200 (metachromatic leukodystrophy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Atezolizumab in non-small cell lung cancer]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (small cell lung cancer) - Addendum to Commission A19-86]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC) - Benefit assessment according to § 35a SGB V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V - Addendum]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC, first line) – addendum to Project A24-97]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC, combination chemotherapy with paclitaxel) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC, combination chemotherapy with nab-paclitaxel) - Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC, adjuvant) - Addendum to Commission A22-67]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (non-small cell lung cancer) - Addendum to A17-50]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (hepatocellular carcinoma) - Addendum to Commission A20-97]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (breast cancer) - Addendum to Commission A19-81]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Atazanavir/cobicistat (Evotaz®) in HIV infection]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ataluren - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ataluren - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [At a glance: screening and management algorithm management of precancerous lesions - cervical cancer and population-based screening]
2006     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Association between nursing capacity and quality of outcome in inpatient care]
2017     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Assistive technology – digital tools that involve social stimulation for mental health in later life. An evidence map]]
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Assisted reproduction]
2012     Basque Office for Health Technology Assessment (OSTEBA) [Assistance at normal childbirth. Guide for pregnant women, future parents, as well as their partners and relatives]
2009     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Assessments tools for risk prediction of cardiovascular diseases]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Assessment process of the research projects submitted to the 2010 call for topics of la Fundació La Marató de TV3. Acquired spinal cord and brain injuries]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Assessment process of research projects submitted to the 2009 calling of the Fundacio La Marato de TV3. Rare diseases]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Assessment on nucleic acid amplification techniques (NAT) for human immunodeficiency, hepatitis C and hepatitis B virus screening in blood banks]
2025     The Danish Health Technology Council (DHTC) [Assessment of treatment of knee pain]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Assessment of the volume-result relationship in specialized care of pediatric cancer]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of the systematic treatment of parodontopathies]
2015     Haute Autorite de sante (HAS) [Assessment of the safety and conditions for conducting autologous fat grafting in reconstructive, restorative and cosmetic breast surgery]
2014     Haute Autorite de sante (HAS) [Assessment of the risks associated with aesthetic mesotherapy practices]
2006     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Assessment of the re-designed diagnosis process for colorectal cancer]
2009     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Assessment of the re-designed diagnosis process for colorectal cancer]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Assessment of the quality of the registration of administrative variables of the minimum basic data set of short-term hospitals of Osakidetza-Basque Health Service in 2005]
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Assessment of the PARLER (Programme d'Accès Rapide Lavallois en Rhumatologie) program]
2023     Center for Drug Evaluation (CDE) [Assessment of the optimal implementation strategy for pneumococcal vaccination policies in groups at high risk of invasive pneumococcal disease]
2015     Haute Autorite de sante (HAS) [Assessment of the measurement of cytomegalovirus viral load by gene amplification in allograft recipients]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of the LEADER study on liraglutide - rapid report]
2023     Haute Autorite de sante (HAS) [Assessment of the exhaled nitric oxide measurement for asthma management]
2023     Haute Autorite de sante (HAS) [Assessment of the Endotest® saliva test in complex endometriosis diagnosis situations]
2024     Haute Autorite de sante (HAS) [Assessment of the endoscopic transluminal necrosectomy procedure in the treatment of acute necrotizing pancreatitis]
2006     Basque Office for Health Technology Assessment (OSTEBA) [Assessment of the effectiveness of the intraoperative detection of the sentry ganglion in solid tumours]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [Assessment of the effectiveness of sublingual immunotherapy and subcutaneous immunotherapy in allergic rhinitis and asthma]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of the benefit of screening in persons under 55 years of age with a family history of colorectal cancer]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of the application of fluoride varnish on milk teeth to prevent the development and progression of initial caries or new carious lesions - rapid report]
2002     Finnish Office for Health Care Technology Assessment (Finohta) [Assessment of telemedicine in the Northern Ostrobothnia hospital district]
2025     The Danish Health Technology Council (DHTC) [Assessment of supervised gait training]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of stereotactic radiosurgery for the treatment of patients with brain metastases]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of stereotactic radiosurgery (SRS) for the treatment of vestibular schwannoma requiring intervention]
2014     Haute Autorite de sante (HAS) [Assessment of spinal cord stimulation]
2025     The Danish Health Technology Council (DHTC) [Assessment of SelfBack App for lower back pain]
2014     Haute Autorite de sante (HAS) [Assessment of real-time optical endomicroscopy performed during mapping of Barrett's esophagus (BE) (for diagnosis of BE-associated early neoplasia)]
2019     Haute Autorite de sante (HAS) [Assessment of pulp wound protection by direct pulp capping]
2025     The Danish Health Technology Council (DHTC) [Assessment of point-of-care tests for use at home for elderly patients]
2023     The Danish Health Technology Council (DHTC) [Assessment of pocket-sized handheld ultrasound devices for point-of-care examination of patients in emergency departments]
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [Assessment of Perinatal Outcome after Sustained Tocolysis for Early Labour (APOSTEL II)]
2025     The Danish Health Technology Council (DHTC) [Assessment of percutaneous vertebroplasty (PVP) for compression fractures]
2024     The Danish Health Technology Council (DHTC) [Assessment of non-surgical treatment of distal radius fractures in patients older than 65 years]
2014     Haute Autorite de sante (HAS) [Assessment of non-invasive methods for measuring liver fibrosis in chronic hepatitis B. Initial assessment and follow-up of non-treated adult patients]
2025     The Danish Health Technology Council (DHTC) [Assessment of Merlin Assay for diagnosis of malignant melanoma]
2010     Haute Autorite de sante (HAS) [Assessment of medical devices for home infusion]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of lung cancer screening using low-dose computed tomography]
2010     Basque Office for Health Technology Assessment (OSTEBA) [Assessment of healthcare status and therapeutic recommendations concerning attention deficit hyperactivity disorder]
2025     The Danish Health Technology Council (DHTC) [Assessment of HAL-assisted TUR-BT]
2011     Haute Autorite de sante (HAS) [Assessment of glomerular filtration rate and serum creatinine levels in the diagnosis of chronic kidney disease in adults]
2025     The Danish Health Technology Council (DHTC) [Assessment of forearm fractures in children]
2016     Basque Office for Health Technology Assessment (OSTEBA) [Assessment of factors related to the pharmaceutical expenditure in Primary Care, and prescription quality in chronic diseases]
2025     The Danish Health Technology Council (DHTC) [Assessment of endovascular aortic repair (EVAR)]
2014     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Assessment of effectiveness and safety of Cyberknife and Gamma knife radiosurgery in intra and extracraneal lesions' treatment (update)]
2007     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Assessment of effectiveness and cost-effectiveness of HPV testing in primary screening for cervical cancer]
2009     Haute Autorite de sante (HAS) [Assessment of drug-eluting stents]
2024     The Danish Health Technology Council (DHTC) [Assessment of domiciliary non-invasive ventilation for patients with chronic obstructive pulmonary disease]
2015     Haute Autorite de sante (HAS) [Assessment of diagnostic and therapeutic parotid and submandibular sialendoscopy]
2015     Haute Autorite de sante (HAS) [Assessment of cardiovascular magnetic resonance compared to coronography and computed tomography]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of cardiac magnetic resonance imaging in coronary heart disease]
2009     Haute Autorite de sante (HAS) [Assessment of breast implants, tissue expanders and external breast prostheses]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Assessment of bilateral cochlear implants in children. Indication criteria for cochlear implants in children and adults]
2012     Haute Autorite de sante (HAS) [Assessment of an epiretinal prosthesis and its implantation procedure]